Applied Genetic Technologies Corp (AGTC) Given Average Rating of “Hold” by Analysts
Shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) have earned a consensus recommendation of “Hold” from the eight research firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $10.17.
Several research analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Applied Genetic Technologies from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Wedbush reaffirmed an “outperform” rating and issued a $9.00 price target on shares of Applied Genetic Technologies in a report on Wednesday, November 8th. ValuEngine cut shares of Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Cantor Fitzgerald set a $9.00 target price on Applied Genetic Technologies and gave the company a “hold” rating in a research note on Friday, October 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Applied Genetic Technologies in a research note on Wednesday, November 8th.
Applied Genetic Technologies (AGTC) traded down $0.10 during trading on Tuesday, hitting $4.20. 41,300 shares of the stock traded hands, compared to its average volume of 117,300. The company has a market capitalization of $75.99, a PE ratio of -21.00 and a beta of 1.62. Applied Genetic Technologies has a 52-week low of $3.25 and a 52-week high of $9.60.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nine Chapters Capital Management LLC bought a new position in Applied Genetic Technologies in the third quarter valued at $113,000. Virtu KCG Holdings LLC bought a new position in Applied Genetic Technologies in the second quarter valued at $178,000. Citadel Advisors LLC increased its stake in Applied Genetic Technologies by 304.6% in the third quarter. Citadel Advisors LLC now owns 41,270 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 31,070 shares during the last quarter. Ativo Capital Management LLC bought a new position in Applied Genetic Technologies in the second quarter valued at $439,000. Finally, ClariVest Asset Management LLC increased its stake in Applied Genetic Technologies by 18.5% in the third quarter. ClariVest Asset Management LLC now owns 99,013 shares of the biotechnology company’s stock valued at $391,000 after acquiring an additional 15,491 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/16/applied-genetic-technologies-corp-agtc-given-average-rating-of-hold-by-analysts.html.
Applied Genetic Technologies Company Profile
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.